Exelixis | EXEL - 销售收入



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 16.3B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


销售 更改 日
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Amgen USD 10.1B 1.48B 2026-06
AstraZeneca USD 15.38B 90M 2026-06
Bayer EUR 10.87B 2.54B 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Cytokinetics USD 28.6M 9.25M 2026-06
Eisai JPY 234.33B 28.9B 2026-06
Eli Lilly USD 22.97B 3.17B 2026-06
Exelixis USD 628.69M 17.89M 2026-06
Genmab DKK 1.16B 259M 2026-06
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.67B 400M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
MacroGenics USD 20.8M 20.43M 2026-03
Merck USD 16.6B 310M 2026-06
Moderna USD 100M 289M 2026-06
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 959M 148M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Pfizer USD 15.03B 530M 2026-06
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sanofi EUR 12.14B 65M 2026-03
Takeda JPY 1.22T 130B 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Xencor USD 51.22M 46.71M 2026-06